Effect of ABT-263 on Intestinal Fibrosis in Human Myofibroblasts, Human Intestinal Organoids, and the Mouse Salmonella typhimurium Model. Issue 2 (1st February 2022)

• Record Type: Journal Article
• Authors: Johnson, Laura A; Rodansky, Eva S; Tran, Anhdao; Collins, Stephen G; Eaton, Kathryn A; Malamet, Benjamin; Steiner, Calen A; Huang, Sha; Spence, Jason R; Higgins, Peter D R
• Is Part Of: Inflammatory bowel diseases. Volume 28:Issue 2(2022)
• Publication Date: 2022-02-01
• Subjects: inflammatory bowel disease -- Crohn's disease -- fibrosis -- myofibroblast -- Bcl-2 -- ABT-263 -- navitoclax -- BH-3 mimetic; Inflammatory bowel diseases -- Periodicals; Colitis, Ulcerative -- Periodicals; Crohn Disease -- Periodicals; Inflammatory Bowel Diseases -- Periodicals; 616.344
• DOI: 10.1093/ibd/izab166
• Languages: English
• ISSNs: 1078-0998

Abstract

Abstract : Lay Summary: Intestinal fibrosis is a common complication of Crohn's disease, yet no effective therapies exist to treat fibrostenotic disease. We report ABT-263 (navitoclax) reduces intestinal fibrosis in in vitro models and reduces inflammation and fibrosis in a mouse IBD model.